Jyoti S. Mayadev, MD, Details Durvalumab’s Impact on Treatment Exposure/Delivery in Combination With CRT in Locally Advanced Cervical Cancer

Video

Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.

During the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, CancerNetwork® spoke with Jyoti S. Mayadev, MD, about how durvalumab (Infinzi) in combination with chemoradiotherapy (CRT) affected treatment exposure and delivery in patients with high-risk locally advanced cervical cancer based on data from the phase 3 CALLA trial (NCT03830866).

Mayadev, a radiation oncologist and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine, detailed the regimen’s promising relative dose intensity and delivery data.

Transcript:

In terms of the treatment exposure and delivery, durvalumab had no impact in terms of the ability to deliver timely and safe radiation. The durvalumab/placebo relative dose intensity was excellent across the board in roughly 96% of the durvalumab/chemoradiation arm and 95% of the placebo/CRT arm. Patients received chemoradiation 99% to 100% of the time. In terms of the number of cycles of concurrent chemotherapy and cisplatin in patients, more than 86% to 88% of patients received more than 5 cycles of chemotherapy. The radiation itself was delivered per protocol in terms of the external beam radiation in [approximately] 96% of the time in the durvalumab arm and 98% in the placebo arm. And brachytherapy, most importantly, was delivered in [about] 95% of the entire population, with 94% being per protocol. These are very high numbers in terms of the quality that we see on the CALLA clinical trial.

Reference

Mayadev JS, Rong, Y, Toita T, et al. Durvalumab in combination with chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC): radiotherapy (RT) delivery and subgroup analyses from CALLA. Presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting; October 23-26, 2022; San Antonio, TX; LBA 03. Accessed October 27, 2022.

Recent Videos
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
Related Content